Ranexa Could Be First Approval For First-Line Angina With MERLIN Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics’ Ranexa could receive the first approval for first-line treatment of chronic angina if a new outcomes trial does not detect a trend towards death or arrhythmia, the company said.